CStone Pharmaceuticals (2616.HK)
Company Info
ISIN | KYG2588M1006 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | HK$1.15B |
---|---|
Revenue (TTM) | HK$481.07M |
Gross Profit (TTM) | HK$136.89M |
EBITDA (TTM) | -HK$770.33M |
Year Range | HK$0.80 - HK$3.33 |
Target Price | HK$5.55 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in CStone Pharmaceuticals, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
CStone Pharmaceuticals had a return of -61.23% year-to-date (YTD) and -73.49% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -61.23% | 5.57% |
1 month | -6.38% | -4.16% |
6 months | -58.10% | 20.07% |
1 year | -73.49% | 20.82% |
5 years (annualized) | -43.28% | 11.56% |
10 years (annualized) | N/A | 10.37% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | -28.19% | -1.84% | -41.25% | |||||||||
2023 | 13.51% | 9.52% | -1.30% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 2616.HK is 3, indicating that it is in the bottom 3% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
CStone Pharmaceuticals(2616.HK)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for CStone Pharmaceuticals (2616.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the CStone Pharmaceuticals. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CStone Pharmaceuticals was 95.49%, occurring on Apr 8, 2024. The portfolio has not yet recovered.
The current CStone Pharmaceuticals drawdown is 95.16%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-95.49% | Jun 22, 2021 | 688 | Apr 8, 2024 | — | — | — |
-58.31% | Mar 25, 2019 | 275 | May 6, 2020 | 276 | Jun 17, 2021 | 551 |
-6.76% | Mar 7, 2019 | 2 | Mar 8, 2019 | 7 | Mar 19, 2019 | 9 |
-3.88% | Feb 28, 2019 | 1 | Feb 28, 2019 | 1 | Mar 1, 2019 | 2 |
-0.12% | Jun 18, 2021 | 1 | Jun 18, 2021 | 1 | Jun 21, 2021 | 2 |
Volatility
Volatility Chart
The current CStone Pharmaceuticals volatility is 21.13%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |